The incomplete understanding of the relationship between phenotype and cancer genotype limits the efficacy of genome-based cancer therapeutic matching. This gap can be bridged by functional testing of live patient tumor tissues, which holds immense potential to increase the predictive power of current stratification biomarkers and reduce the dismal >90% failure rate of oncology clinical trials. MISO Chip, a Montreal-based startup, offers a groundbreaking solution by leveraging 3D tumor explant models and novel microfluidic systems that maximize the use of live patient tissues ex vivo. In this talk, CEO Etienne Laurent will highlight the significance and the context of use of Patient-Derived Explants (PDE) in oncology, introduce MISO Chip's state-of-the-art microfluidic systems, and demonstrate how optimal oxygenation of micro-tissues overcomes the traditional limitations of PDE.

Co-author: Thomas Gervais